NASDAQ:XNPT - XenoPort Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$7.07Today's Range$7.07 - $7.0752-Week Range$3.35 - $7.86VolumeN/AAverage Volume1.22 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email XenoPort, Inc. is a biopharmaceutical company. The Company is focused on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States. The Company's segment is the development and commercialization of product candidates for the treatment of neurological and other disorders. Its development-stage product candidates include XP23829, XP21279 and arbaclofen placarbil. HORIZANT has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. XP23829 is a fumaric acid ester compound and a prodrug of metabolite monomethyl fumarate being developed for the treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or patients with relapsing forms of multiple sclerosis. XP21279 is a Transported Prodrug of levodopa being developed for the treatment for patients with idiopathic Parkinson's disease. Receive XNPT News and Ratings via Email Sign-up to receive the latest news and ratings for XNPT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryPharmaceuticals SectorN/A Current SymbolNASDAQ:XNPT Previous Symbol CUSIP98411C10 Webwww.xenoport.com Phone+1-408-6167200Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A OptionableNot Optionable XenoPort (NASDAQ:XNPT) Frequently Asked Questions What is XenoPort's stock symbol? XenoPort trades on the NASDAQ under the ticker symbol "XNPT." Has XenoPort been receiving favorable news coverage? Headlines about XNPT stock have trended positive recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. XenoPort earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the company's share price in the next several days. How do I buy shares of XenoPort? Shares of XNPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is XenoPort's official website? The official website for XenoPort is http://www.xenoport.com/. How can I contact XenoPort? XenoPort's mailing address is 2000 Seaport Blvd Ste 300, REDWOOD CITY, CA 94063-5584, United States. The biopharmaceutical company can be reached via phone at +1-408-6167200. MarketBeat Community Rating for XenoPort (NASDAQ XNPT)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 132 (Vote Outperform)Underperform Votes: 136 (Vote Underperform)Total Votes: 268MarketBeat's community ratings are surveys of what our community members think about XenoPort and other stocks. Vote "Outperform" if you believe XNPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNPT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: How accurate is the Rule of 72?